BiotechTube

coformulated TDF/FTC

Pre-clinicalCompleted
0 watching 0 views this week💤 Quiet
22
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

HIV Chemoprophylaxis

Conditions

HIV Chemoprophylaxis, HIV Preexposure Prophylaxis

Trial Timeline

Oct 1, 2014 → Nov 1, 2018

NCT ID
NCT02074891

About coformulated TDF/FTC

coformulated TDF/FTC is a pre-clinical stage product being developed by Gilead Sciences for HIV Chemoprophylaxis. The current trial status is completed. This product is registered under clinical trial identifier NCT02074891. Target conditions include HIV Chemoprophylaxis, HIV Preexposure Prophylaxis.

Hype Score Breakdown

Clinical
5
Activity
2
Company
9
Novelty
2
Community
1

Clinical Trials (1)

NCT IDPhaseStatus
NCT02074891Pre-clinicalCompleted

Other Products from Gilead Sciences

Ranolazine + PlaceboApproved
84
Truvada + Atazanavir + RitonavirApproved
84
Truvada + efavirenzApproved
84
B/F/TAF + Atripla + B/F/TAF Placebo + Atripla PlaceboApproved
84
TDF + Placebo Vaginal Gel + Vaginal TFV Gel + Placebo TabletsApproved
84